peterschreiber.media
Celldex Therapeutics' (NASDAQ:CLDX) coverage was initiated at neutral by Goldman Sachs, due in part to concerns about the market opportunity for its drug candidate barzolvolimab in chronic urticaria and a lack of meaningful near-term catalysts.
The investment bank said “strong statistical